KAWASHIRI Masaaki Last updated: Oct 14, 2018 at 11:51
Name
KAWASHIRI Masaaki Affiliation
Kanazawa University Section
Hospital, Hospital, Cardiovascular Medicine
Academic & Professional Experience
2002
-
2003
: Kanazawa University
2003
-: Kanazawa University Hospital
1998
-
2000
: University of Pennsylvania, School of Medicine
1994
-
1995
: Kanazawa University Hospital
Education
Internal medicine II, Graduate School, Division of Medicine, Kanazawa University
-
1994
Faculty of Medicine, Niigata University
Committee Memberships
2004
Japan Atherosclerosis Society
2004
-: Japan Atherosclerosis Society
Published Papers
Kawashiri MA, Tada H, Nomura A, Yamagishi M
Journal of cardiology 72(4) 307-313 Oct 2018 [Refereed]
Tada H, Nohara A, Inazu A, Sakuma N, Mabuchi H, Kawashiri MA
Journal of atherosclerosis and thrombosis 25(9) 783-789 Sep 2018 [Refereed]
Tada H, Kawashiri MA, Nomura A, Teramoto R, Hosomichi K, Nohara A, Inazu A, Mabuchi H, Tajima A, Yamagishi M
Journal of clinical lipidology Aug 2018 [Refereed]
Tada H, Kawashiri MA, Nomura A, Yoshimura K, Itoh H, Komuro I, Yamagishi M
European journal of preventive cardiology 2047487318796989 Aug 2018 [Refereed]
Tada H, Kawashiri MA
Journal of atherosclerosis and thrombosis Aug 2018 [Refereed]
Misc
Lp(a)の新展開 重症家族性高コレステロール血症の治療選択におけるLp(a)の意義
川尻 剛照
日本動脈硬化学会総会プログラム・抄録集 50回 222-222 Jun 2018
私の処方 家族性高コレステロール血症ヘテロ接合体に対する私の処方
川尻 剛照
Modern Physician 38(4) 405-405 Apr 2018
【プレシジョンメディシンの現状と未来】 脂質代謝特論 高LDL-Cのプレシジョンメディシン
多田 隼人, 川尻 剛照, 山岸 正和
The Lipid 29(2) 146-152 Apr 2018
高コレステロール血症および網膜症を有する糖尿病患者において血清中トリグリセリドは初回心血管イベントを予測する 無作為化対照試験の事後解析(Serum Triglyceride Predicts First Cardiovascular Events in Diabetic Patients with Hypercholesterolemia and Retinopathy: Post-hoc Analysis of a Randomized Controlled Trial)
多田 隼人, 野村 章洋, 川尻 剛照, 山岸 正和, 小室 一成, 伊藤 裕
日本循環器学会学術集会抄録集 82回 LBCT1-3 Mar 2018
重度高トリグリセリド血症における臨床的全エクソームシーケンシング(Clinical Whole Exome Sequencing in Severe Hypertriglyceridemia)
多田 隼人, 野村 章洋, 川尻 剛照, 野原 淳, 山岸 正和
日本循環器学会学術集会抄録集 82回 OJ11-8 Mar 2018
Conference Activities & Talks
Impact of evolocumab, a PCSK9 inhibitor, withdrawing from regular LDL-apheresis therapy in patients with heterozygous familial hypercholesterolemia
KAWASHIRI Masaaki
European Society of Cardiology 2017 Aug 2017
Impact of evolocumab, a PCSK9 inhibitor, withdrawing from regular LDL-apheresis therapy in patients with heterozygous familial hypercholesterolemia.
KAWASHIRI Masaaki
Mar 2017
Who has extreme high cardiovascular risk in patients with familial hypercholesterolemia?
KAWASHIRI Masaaki
10th Asian-Pacific Society of Atherosclerosis & Vascular Diseases Jul 2016
Impact of combined lipid lowering with calcium channel antagonist-based blood pressure control on coronary plaque regression: MILLION Study.
KAWASHIRI Masaaki
The Society for Cardiovascular Angiography and Intervention Foundation May 2015
Vascular complication in Japanese FH patients.
KAWASHIRI Masaaki
The Satellite Symposium of the 17th International Symposium on Atherosclerosis May 2015
Research Grants & Projects
Molecular Genetic Research of Atherosclerogenesis
Project Year: 2002
